Endo International has entered into a definitive agreement with Boston Scientific, under which Boston Scientific will acquire Endo's American Medical Systems' (AMS) Men's and Prostate Health businesses for up to $1.65 billion, with $1.6 billion in cash payable at closing.
Endo International has announced changes to its executive leadership and senior management team...
Endo International announced today that Caroline B...
Endo International’s $2.6 billion purchase of Auxilium Pharmaceuticals complements Endo’s...
Ireland's Endo International is buying Auxilium Pharmaceuticals Inc. in a sweetened cash-and-stock deal valued at $2.6 billion a few weeks after Auxilium rejected a lower bid for the company. Endo says it will pay $33.25 in cash and stock for each Auxilium share.
Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.
Endo International PLC says it is making an unsolicited offer for Auxilium Pharmaceuticals that values Auxilium at $28.10 per share. The deal is worth $1.41 billion in cash and stock, based on Auxilium's shares outstanding. Endo values the offer at $2.2 billion.
Some of the nation's largest cities are ratcheting up their criticism of prescription painkillers, blaming the industry for a wave of addiction and overdoses that have ravaged their communities and busted local budgets.
The Food and Drug Administration says there is little evidence that testosterone-boosting drugs taken by millions of American men are beneficial, though the agency is also unconvinced by studies suggesting the hormone carries serious risks.
Endo and BioDelivery Sciences Announce Phase III Results for BEMA buprenorphine in Opioid-Experienced Patients with Chronic PainJuly 7, 2014 8:10 am | News | Comments
BEMA buprenorphine is being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in both patients who are opioid naive and opioid experienced.
Endo International has reached a definitive agreement to acquire DAVA Pharmaceuticals, Inc., a privately-held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones.
The lawsuit filed Monday in Cook County Circuit Court states the city has paid nearly $9.5 million for filling opioid prescriptions since 2007. It alleges the pharmaceutical companies' marketing of opioids for long-term use to treat non-cancer pain was false, misleading and "unsupported by science."
Asana BioSciences, an Amneal Alliance Company, Acquires Branded Drug Discovery Platform from Endo InternationalJune 3, 2014 8:12 am | News | Comments
Asana BioSciences, an independent member of the Amneal Alliance of Companies, has acquired the early stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc.
Two California counties have filed a lawsuit accusing five drug companies of waging a campaign of deception to boost the sales of painkillers behind the nation's prescription drug addiction problem.
Endo International has entered into a definitive agreement under which Endo will acquire Grupo Farmaceutico Somar, a privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for cash consideration.
Endo International has appointed Susan Hall, Ph.D. as executive vice president, chief scientific officer and global head of research & development and quality, effective March 10, 2014.
Endo Pharmaceuticals has received FDA approval of AVEED (testosterone undecanoate) injection for the treatment of adult men with hypogonadism (commonly known as Low-T) that is associated with a deficiency or absence of the male hormone testosterone.
Endo Health Solutions Inc. has announced that, at the shareholder meeting held today, proposals related to Endo's proposed acquisition of Paladin Labs Inc. were approved by Endo's shareholders.
Endo Health will pay almost $193 million to resolve claims that it improperly marketed the shingles treatment Lidoderm for unapproved uses like treating lower back pain.
Endo Health Solutions today announced that its Qualitest subsidiary has completed the acquisition of privately held Boca Pharmacal, a specialty pharmaceutical company, for approximately $225 million in cash.
Endo Health Solutions said Thursday it will sell its HealthTronics urology unit for up to $130 million as it streamlines its business. Investment firm Altaris Capital Partners will pay $85 million upfront for HealthTronics, and Endo could get an additional $45 million based on the performance of the business.
Endo Health Solutions will acquire NuPathe Inc. for $2.85 per share in cash, or approximately $105 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment ZECUITY are achieved over time.
Endo Health is buying the Canadian specialty drug maker Paladin Labs for about $1.5 billion, and both will then be folded into a newly-formed Irish holding company.
Endo Health Solutions said Monday that former Becton Dickinson executive Suketu Upadhyay will join the company as chief financial officer Sept. 23. Upadhyay has been Becton Dickinson & Co.'s chief accounting officer and was interim CFO from November 2012 to July 2013.
Endo Health Solutions said Thursday that regulators accepted for review new data for its long-acting testosterone injection Aveed and will make a ruling on the drug by Feb. 28. The Food and Drug Administration asked Endo for more information in May. Endo said the FDA was concerned about risks and...
Endo Health Solutions announced that its Qualitest subsidiary has reached a definitive agreement to acquire privately held Boca Pharmacal, a specialty generics company, for $225 million in cash. The transaction is expected to enhance the growth platform and pipeline for Endo's Qualitest business and is consistent with Endo's strategic transformation into a leading specialty healthcare company.
Endo Health Solutions Inc. said Tuesday its net income rose in the second quarter despite a series of charges related to its planned shift in business strategy and an allowance for potential lawsuits. The company also raised its full-year guidance, but shares slipped in afternoon trading In June...
Endo Health Solutions Inc. on Wednesday partially reversed course on several years of expansion, saying it will explore strategic options for two businesses and eliminate almost 700 jobs. The company said it will consider options for its HealthTronics urology business and for its branded drug...
Endo Health Solutions Inc. said Thursday the Food and Drug Administration wants more information about its long-acting testosterone injection Aveed before it will approve the drug. Endo said the FDA is concerned about risks and severe complications related to post-injection reactions. Endo said...
- Page 1